The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer

Journal Article · Tue Jul 10 00:00:00 EDT 2012 · Journal of Medicinal Chemistry

DOI:https://doi.org/10.1021/jm3005866· OSTI ID:1495460

Lewis, Richard T. ^[1]; Bode, Christiane M. ^[1]; Choquette, Deborah M. ^[1]; Potashman, Michele ^[1]; Romero, Karina ^[1]; Stellwagen, John C. ^[1]; Teffera, Yohannes ^[1]; Moore, Earl ^[1]; Whittington, Douglas A. ^[1]; Chen, Hao ^[1]; Epstein, Linda F. ^[1]; Emkey, Renee ^[1]; Andrews, Paul S. ^[1]; Yu, Violeta L. ^[1]; Saffran, Douglas C. ^[1]; Xu, Man ^[1]; Drew, Allison ^[1]; Merkel, Patricia ^[1]; Szilvassy, Steven ^[2]; Brake, Rachael L. ^[1]

---

1. Amgen Inc., 360 Binney Street, Cambridge Massachusetts 02142, United States
2. Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States

• Research Organization: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
• Sponsoring Organization: INDUSTRY
• OSTI ID: 1495460
• Journal Information: Journal of Medicinal Chemistry, Vol. 55, Issue 14; ISSN 0022-2623
• Publisher: American Chemical Society (ACS)
• Country of Publication: United States
• Language: ENGLISH